NGGT006

NGGT006 is an investigational gene therapy drug developed for familial hypercholesterolemia. It uses an adeno-associated viral (AAV) vector carrying a codon-optimized human LDLR gene to drive the expression of LDLR protein with normal function, promoting the clearance of low-density lipoprotein cholesterol (LDL-C)[1][4][5]. ## Clinical Development NGGT006 has demonstrated effectiveness in both transgenic HoFH (Homozygous Familial Hypercholesterolemia) mouse and hamster models. In a proof-of-concept Investigator-Initiated Trial (IIT), three doses were tested in four HoFH patients. In the high dose cohort, two patients experienced significant reduction in plasma LDL-C, with levels decreasing to 3.87mmol/L after one week and 1.58mmol/L after two weeks, representing over 90% reduction in LDL-C[5]. Currently, NGGT006 is being evaluated in early phase 1 clinical trials: 1. An open-label, single-center, dose-escalation pilot trial to evaluate safety and efficacy in patients with refractory hypercholesterolemia diagnosed by gene testing for familial hypercholesterolemia[9]. 2. The trial will enroll 3-9 subjects divided into 3 groups according to dose escalation principles, receiving intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg), and high dose (3e13vg/kg)[9]. 3. All subjects will undergo 52 weeks of treatment observation followed by 260 weeks of long-term follow-up[9]. ## Mechanism of Action NGGT006 functions by delivering a functional copy of the LDLR gene to liver cells. The LDLR (Low-Density Lipoprotein Receptor) protein plays a crucial role in removing LDL cholesterol from the bloodstream. In patients with familial hypercholesterolemia, mutations in the LDLR gene lead to dysfunctional LDL receptors, resulting in elevated blood cholesterol levels. By providing a functional copy of the LDLR gene, NGGT006 aims to restore normal cholesterol clearance mechanisms[1][4][9]. ## Development Status NGGT006 is currently in Phase 1 clinical trials for hypercholesterolemia and hyperlipoproteinemia type II[2][4]. According to available information, the primary completion date for one of the trials (NGGT006-P-2301) is expected to be November 30, 2024, while another trial (NGGT006-P-2302) has a primary completion date of March 31, 2025[4]. The company behind NGGT006 appears to be Next Generation Gene Therapeutics (NGGT), a clinical-stage biotechnology company developing novel gene therapies for various conditions including retinal, metabolic, and neurodegenerative diseases[5][7].